What Makes Abbott Laboratories (ABT) a Compelling Investment Opportunity with Reliable Growth
Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Diamond Hill Capital Ric Dillon | 4,936,774 | $447,962,873 | -9% | 3.59% |
| 2. | Fisher Asset Management Ken Fisher | 505,421 | $45,862,039 | -33% | 0.01% |
| 3. | Walleye Capital Will England | 329,761 | $29,922,513 | -19% | 0.11% |
| 4. | 140,800 | $12,776,192 | +18% | 0.05% | |
| 5. | Lee Munder Capital Group Lee Munder | 99,294 | $9,009,938 | -3% | 0.48% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $86.82 | 2,000 | $173,640.00 | 23,319 | 2026-05-07 | Filing | |
| $92.65 | 10,000 | $926,537.00 | 6,751,103 | 2026-04-27 | Filing | |
| $91.50 | 2,200 | $201,300.00 | 2,200 | 2026-04-23 | Filing | |
| $108.33 | 5,033 | $545,238.98 | 6,738,817 | 2026-02-04 | Filing | |
| $109.14 | 4,967 | $542,092.42 | 6,733,784 | 2026-02-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $115.58 | 709 | $81,946.22 | 39,164 | 2026-03-02 | Filing | |
| $115.58 | 885 | $102,288.30 | 146,377 | 2026-03-02 | Filing | |
| $115.58 | 1,144 | $132,223.52 | 76,843 | 2026-03-02 | Filing | |
| $115.58 | 613 | $70,850.54 | 104,291 | 2026-03-02 | Filing | |
| $115.58 | 585 | $67,614.30 | 24,628 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 152,563,476 | $13,843,609,746 | 0.21% | |
| 2. | 80,926,234 | $7,343,246,473 | 0.22% | |
| 3. | 16,706,669 | $1,515,963,144 | 0.44% | |
| 4. | 13,359,956 | $1,223,914,626 | 0.39% | |
| 5. | 9,991,899 | $906,664,945 | 0.15% |
News See All
Abbott vs Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices...
Here’s Why These 3 ETFs Are Beating the S&P 500 Index in 2026
The S&P 500 Index (SPX) has gained 9.4% so far this year, but a few low‑cost ETFs are doing even better. These funds do not rely on big tech stocks
3 ‘Strong Buy’ Dividend Aristocrat Stocks to Power Your Cash Flow, 7/30/26
Investors searching for regular cash payments can look to Abbott Laboratories ($ABT), CH Robinson ($CHRW), and Linde ($LIN). Top analysts covering ...
SCHD vs. VYMI: Which Dividend ETF Comes Out on Top?
Dividend ETFs are one of the most popular ways to earn passive income, but choosing the right fund isn’t always easy. Among the leading options are...
Abbott (ABT) Raised Its Profit Forecast. What's Driving Its Growth?
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices...
Abbott Laboratories (ABT) Fell as Guidance and Litigation Concerns Overshadowed Growth
Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the "Jensen Quality Growth Equity Strategy".
12 Best Monopoly Stocks to Buy According to Hedge Funds
RBC Wealth Management noted that the consensus 2026 earnings growth forecast for the S&P 500 saw an increase from 13.6% at the start of the year to 23.3% by the end of June.
Is Abbott Laboratories (ABT) Stock Still a Healthcare Growth Opportunity After Analyst Target Cut?
TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares.
10 Best Innovative Healthcare Stocks to Buy Now
The U.S. healthcare sector has lagged behind the entire market for three consecutive years, with returns of just 0.3% in 2023, 0.9% in 2024, and 12.5% in 2025.
Hedge Fund Resource Center